Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
31 Gennaio 2024 - 2:45PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that the
Company will ring the Nasdaq Stock Market Closing Bell on Thursday,
February 1, 2024 to celebrate the closing of its initial public
offering and listing onto Nasdaq.
Lori Bisson, Chief Executive Officer of
Autonomix, will perform the honorary Nasdaq closing bell ringing
ceremony to be held from 3:50 to 4:00 p.m. ET. A live webcast of
the ceremony will be available at:
https://new.livestream.com/nasdaq/live. The Company's executive
management team, Board of Directors, family members and other
supporters will join in the ceremony.
Ms. Bisson commented, “It is an honor to
recognize the incredible efforts of our team and the significant
achievement of closing our IPO and listing on Nasdaq. Autonomix is
pleased to join Nasdaq’s prestigious community of innovative and
growth-oriented companies. Our Nasdaq listing represents a pivotal
moment in the growth of our Company and a significant corporate
milestone leading to what we believe will be an exciting future for
Autonomix.”
Follow the Event on Social Media:
For multimedia features such as exclusive
content, photo postings, status updates and video of bell
ceremonies, please visit Nasdaq’s Facebook
page:http://www.facebook.com/nasdaq.
For photos from ceremonies and events, please visit Nasdaq’s
Instagram page:http://instagram.com/nasdaq
For news tweets, please visit Nasdaq’s Twitter
page:http://twitter.com/nasdaq
Webcast:A live stream of the Nasdaq Closing
Bell will be available at:
https://www.nasdaq.com/marketsite/bell-ringing-ceremony
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and need an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Such forward-looking statements can be identified by
the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’
‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’
‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the final offering
statement filed with the U.S. Securities and Exchange Commission
(“SEC”) on January 26, 2024. Forward-looking statements speak only
as of the date of the document in which they are contained and
Autonomix does not undertake any duty to update any forward-looking
statements except as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Set 2023 a Set 2024